Company Description
RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States.
The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services.
The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products.
The company was formerly known as PolarityTE, Inc. and changed its name to RegenETP, Inc. in August 2023.
RegenETP, Inc. is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 1998 |
| IPO Date | Aug 13, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | David Seaburg |
Contact Details
Address: 1960 S. 4250 West Salt Lake City, Utah 84104 United States | |
| Phone | (385) 266-3151 |
Stock Details
| Ticker Symbol | RGTPQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001076682 |
| Employer ID | 06-1529524 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard Hague | President, Chief Executive Officer and Director |
| Nikolai Sopko M.D., Ph.D. | Chief Scientific Officer and Vice President of Research & Development |
| Rich Haerle | Vice President of Investor Relations and Strategy |
| Mark E. Lehman J.D. | Chief Legal Officer |
| Angela Ziegler | Vice President of Marketing and Public Relations |
| Alain Adam | Vice President of Sales |
| Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D. | Senior Vice President of Corporate Development and President of Contract Services |
| Ryan Mathis M.D. | Chief Medical Officer |
| Kolby Day Esq. | Senior Vice President of Manufacturing Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2023 | 8-K | Current Report |
| Aug 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Aug 15, 2023 | 8-K | Current Report |
| Aug 11, 2023 | 15-12G | Securities registration termination |
| Aug 1, 2023 | 8-K | Current Report |
| Jul 10, 2023 | 25-NSE | Filing |
| Jul 7, 2023 | 8-K | Current Report |
| Jun 8, 2023 | RW | Filing |
| Jun 7, 2023 | 8-K | Current Report |
| Jun 7, 2023 | 8-K | Current Report |